We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




New, Enzyme-Free Glucose Monitoring Sensor Solution Could Find Applications in Range of POC Diagnostics

By LabMedica International staff writers
Posted on 03 Feb 2022

Researchers have developed a new glucose sensor that is cheaper and more robust than current systems, opening up the possibility of taking the underlying applied methodology to a vast range of similar point-of-care diagnostics. More...

Researchers at the University of Bath (Bath, UK) working in collaboration with industrial partner, Integrated Graphene (Stirling, UK) have developed a new sensing technique based on graphene foam for the detection of glucose levels in the blood. Since it is a chemical sensor instead of being enzyme-based, the new technology is robust, has a long shelf-life and can be tuned to detect lower glucose concentrations than current systems.

Many current biosensors use enzymes that bind glucose and produce an electric current proportional to the concentration of glucose in the blood sample. The new technique uses a chemical sensor, which is more robust and is not affected by high temperatures or changes in pH. Furthermore, it has the potential to accurately detect a wider range of glucose concentrations above and below current biosensor ranges, which may be useful in neonatal glucose sensing.

The new sensor is based on the chemical boronic acid, which is attached to a graphene foam surface. An electroactive polymer layer is added on top and binds to the boronic acid. When glucose is present, it competitively binds to the boronic acid, displacing the polymer. The sensor produces an electric current proportional to how much polymer is displaced, meaning that the concentration of glucose in the sample can be accurately measured. The researchers anticipate the sensor will expand the scope of boronic acid - based glucose sensing. Their sensor is based upon electrochemical methods rather than fluorescence, thereby enabling new boronic acid – based glucose sensing approaches.

“We’re excited by our results as this is the first time this approach has been used for glucose sensing,” said Professor Tony James, who is a Royal Society Wolfson Research Merit Award holder at the University of Bath’s Department of Chemistry and helped supervise the project. “We are still in the early stages of optimizing sensitivity and reproducibility but hope this new technology could be used in a wide range of applications, from medical sensing to food production. It could also be adapted to sense other molecules or for use in continuous flow systems.”

“Now, with this project alongside the University of Bath, we are beginning to see some of that potential being realized to create a more cost-effective and therefore accessible platform by using a new, enzyme-free glucose monitoring sensor solution,” said Dr. Marco Caffio, Co-Founder and CSO of Integrated Graphene, said: “When we started Integrated Graphene. “Now that we have proved this technique, it opens up the opportunity to take the underlying applied methodology to a vast range of similar point-of-care diagnostics that could profit from associated benefits such as reduced cost and enhanced shelf-life.”

Related Links:
University of Bath 
Integrated Graphene 


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Droplet Digital PCR System
QX600 AutoDG
New
Multilevel Whole Blood Calibrator Set
6PLUS1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.